BIOMAT Database Logo BIOMAT Database Logo

[Treatment of Raynaud's phenomenon]. 1993

Y Levy, and Y Shoenfeld

UI MeSH Term Description Entries
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D045930 Anabolic Agents These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

Y Levy, and Y Shoenfeld
Treatment of Raynaud's phenomenon.
February 1993, European heart journal,
Y Levy, and Y Shoenfeld
[Treatment of Raynaud's phenomenon].
January 1987, Annales de dermatologie et de venereologie,
Y Levy, and Y Shoenfeld
Treatment of Raynaud's phenomenon.
October 2008, Autoimmunity reviews,
Y Levy, and Y Shoenfeld
[Treatment of Raynaud's phenomenon].
January 2009, Revista clinica espanola,
Y Levy, and Y Shoenfeld
The treatment of Raynaud's phenomenon.
January 1994, Clinics in dermatology,
Y Levy, and Y Shoenfeld
[Surgical treatment of Raynaud's phenomenon].
October 1980, Revue medicale de Liege,
Y Levy, and Y Shoenfeld
[Psychiatric treatment of Raynaud's phenomenon].
November 1979, Lakartidningen,
Y Levy, and Y Shoenfeld
The treatment of Raynaud's phenomenon.
May 1986, The British journal of dermatology,
Y Levy, and Y Shoenfeld
Raynaud's phenomenon and Raynaud's disease definition of Raynaud's phenomenon.
November 1976, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
Y Levy, and Y Shoenfeld
Raynaud's phenomenon after bleomycin treatment.
April 1978, Cancer treatment reports,
Copied contents to your clipboard!